Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRPO 
Precipio Inc (PRPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: PRPO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19
1 Year Target Price $19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.55% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.69M USD | Price to earnings Ratio - | 1Y Target Price 19 |
Price to earnings Ratio - | 1Y Target Price 19 | ||
Volume (30-day avg) 1 | Beta 1.25 | 52 Weeks Range 3.90 - 11.80 | Updated Date 07/1/2025 |
52 Weeks Range 3.90 - 11.80 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.45% | Operating Margin (TTM) -17.43% |
Management Effectiveness
Return on Assets (TTM) -10.9% | Return on Equity (TTM) -25.29% |
Valuation
Trailing PE - | Forward PE 15.43 | Enterprise Value 17908601 | Price to Sales(TTM) 0.83 |
Enterprise Value 17908601 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA -1.15 | Shares Outstanding 1512010 | Shares Floating 1335212 |
Shares Outstanding 1512010 | Shares Floating 1335212 | ||
Percent Insiders 13.98 | Percent Institutions 7.46 |
Analyst Ratings
Rating 1 | Target Price 19 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Precipio Inc
Company Overview
History and Background
Precipio, Inc. was founded in 1997, initially focusing on developing innovative solutions for the diagnostics industry. Over time, it has evolved into a provider of diagnostic services and technologies, primarily in the field of oncology.
Core Business Areas
- Diagnostic Services: Precipio offers a range of diagnostic services, including pathology testing and hematopathology testing. These services are used to diagnose and monitor various diseases, particularly cancers.
- HemeScreen: HemeScreen is Precipio's core technology, a comprehensive hematopathology testing service for bone marrow samples.
- IV Cell: IV Cell is Precipio's core technology that includes cell culture.
Leadership and Structure
The CEO of Precipio is Ilan Danieli. The company has a board of directors and a management team responsible for overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- HemeScreen: HemeScreen is Precipio's core hematopathology testing service. It offers a comprehensive analysis of bone marrow samples. Precise market share data is difficult to obtain, but the hematology diagnostics market is competitive, with competitors including large reference labs like Quest Diagnostics (DGX) and LabCorp (LH), as well as specialized hematology labs and academic medical centers.
- IV Cell: IV Cell is a solution for accelerating oncology drug and treatment development. It grows and maintains cell cultures to optimize drugs before testing on the human body. Market share information is hard to obtain. The market of cell culture and drug development is dominated by players like Thermo Fisher Scientific (TMO) and Danaher (DHR).
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth, driven by aging populations, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. The oncology diagnostics segment is particularly important.
Positioning
Precipio focuses on niche markets within the diagnostics industry, particularly hematopathology and oncology. It aims to provide specialized testing services and technologies to healthcare providers and pharmaceutical companies.
Total Addressable Market (TAM)
The global hematology diagnostics market is estimated to be in the billions of dollars. Precipio, as a smaller player, is positioned to capture a share of this market through its specialized services and technologies. The total addressable market for oncology diagnostics is significantly larger.
Upturn SWOT Analysis
Strengths
- Specialized expertise in hematopathology
- Proprietary technologies like HemeScreen and IV Cell
- Focus on niche markets
- Established relationships with academic medical centers
Weaknesses
- Limited financial resources compared to larger competitors
- Small market share
- Dependence on key technologies
- History of operating losses
Opportunities
- Expanding HemeScreen and IV Cell's applications
- Partnerships with pharmaceutical companies
- Acquisitions of complementary technologies
- Growth in the oncology diagnostics market
Threats
- Competition from larger diagnostic companies (DGX, LH, TMO, DHR)
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- DGX
- LH
- TMO
- DHR
Competitive Landscape
Precipio faces significant competition from larger, more established players in the diagnostics industry. Its competitive advantages lie in its specialized expertise and proprietary technologies. However, it needs to overcome its financial challenges to compete effectively.
Major Acquisitions
Failed to find a historical Acquisition by Precipio
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: Failed to find a historical Acquisition
Growth Trajectory and Initiatives
Historical Growth: Precipio's growth has been uneven, with periods of revenue growth and periods of decline. The company has struggled to achieve profitability.
Future Projections: To be completed with analyst report
Recent Initiatives: Recent initiatives include expanding the applications of HemeScreen and pursuing partnerships with pharmaceutical companies for IV Cell
Summary
Precipio is a small diagnostic company with specialized expertise in hematopathology. Its HemeScreen and IV Cell technologies offer potential for growth, but the company faces significant competition and financial challenges. The company needs to execute its growth strategy and achieve profitability to create long-term value for shareholders. It must look out for the larger players that could replicate its offerings at a faster scale.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precipio Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2000-07-18 | Founder, President, CEO & Director Mr. Ilan Danieli | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 54 | Website https://www.precipiodx.com |
Full time employees 54 | Website https://www.precipiodx.com | ||
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.